Latest Period
Q4 2025
Security Snapshot
RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) Institutional Ownership
CUSIP: 75382E208
13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026
Institutions Reporting
99
Shares (Excl. Options)
27,200,695
Price
$33.87
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, $0.0001 par value
- Symbol
- RAPT
- Shares outstanding
- 27,748,559
- Price per share
- $58.02
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 27,200,695
- Total reported value
- $921,288,979
- % of total 13F portfolios
- 0.01%
- Share change
- +13,577,455
- Value change
- +$461,871,577
- Number of holders
- 99
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- RAPT - RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 75382E208.
- 99 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 99 to 0 between Q4 2025 and Q1 2026.
- Reported value moved from $921,288,979 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 99 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 75382E208?
CUSIP 75382E208 identifies RAPT - RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue With The Right Next Step
- Latest 13F filings - identify new institutional portfolio moves.
- Latest Schedule 13D/13G reports - cross-check beneficial ownership events.
- All institutional ownership pages - compare nearby CUSIPs and holder concentration.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75382E208:
Significant Owners of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ForGrowth III PA B.V. | 7.4% | $47,291,008 | 1,833,333 | ForGrowth III PA B.V. | 23 Oct 2025 | |||
| Redmile Group, LLC | 9.9% | $14,934,463 | 1,765,303 | Redmile Group, LLC | 30 Jun 2025 | |||
| RTW INVESTMENTS, LP | 5.9% | $55,041,487 | 1,637,165 | RTW Investments, LP | 31 Dec 2025 | |||
| VANGUARD GROUP INC | 4.2% | $17,958,239 | 696,188 | The Vanguard Group | 30 Sep 2025 | |||
| Nantahala Capital Management, LLC | 3.8% | -33% | $16,074,692 | -$8,467,788 | 623,282 | -35% | Nantahala Capital Management, LLC | 30 Sep 2025 |
| Deep Track Capital, LP | 0.4% | $3,713,262 | 110,448 | Deep Track Capital, LP | 31 Dec 2025 |
As of 31 Dec 2025, 99 institutional investors reported holding 27,200,695 shares of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT). This represents 98% of the company’s total 27,748,559 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value (RAPT) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 9.3% | 2,582,408 | +58% | 2.9% | $87,466,159 |
| FCPM III SERVICES B.V. | 6.6% | 1,833,333 | +433% | 8.1% | $62,094,989 |
| ORBIMED ADVISORS LLC | 5.9% | 1,642,891 | +51% | 1.2% | $55,644,718 |
| RTW INVESTMENTS, LP | 5.9% | 1,637,165 | +11% | 0.56% | $55,450,779 |
| Foresite Capital Management VI LLC | 5.6% | 1,562,500 | 0% | 16% | $52,921,875 |
| Siren, L.L.C. | 5% | 1,375,000 | +137% | 1.4% | $46,571,250 |
| VANGUARD GROUP INC | 4.3% | 1,186,791 | +70% | 0% | $40,196,611 |
| Frazier Life Sciences Management, L.P. | 3.5% | 983,333 | 0.89% | $33,305,489 | |
| BRAIDWELL LP | 3.4% | 929,694 | 1% | $31,488,736 | |
| Redmile Group, LLC | 3.2% | 885,927 | +60% | 2.2% | $30,006,347 |
| PERCEPTIVE ADVISORS LLC | 3% | 825,890 | +349% | 0.51% | $27,972,894 |
| Soleus Capital Management, L.P. | 2.8% | 764,000 | +42% | 1.1% | $25,876,680 |
| Nantahala Capital Management, LLC | 2.7% | 754,153 | +21% | 1.5% | $25,543,162 |
| Ikarian Capital, LLC | 2.4% | 665,271 | +8.2% | 2.9% | $22,532,728 |
| Caligan Partners LP | 2.3% | 644,400 | 2% | $21,825,828 | |
| STATE STREET CORP | 2.3% | 639,804 | +1611% | 0% | $21,670,161 |
| CITADEL ADVISORS LLC | 2.1% | 591,802 | +3711% | 0.01% | $20,044,334 |
| GREAT POINT PARTNERS LLC | 2.1% | 581,187 | 6.4% | $19,684,804 | |
| Octagon Capital Advisors LP | 2.1% | 574,000 | 2.4% | $19,441,380 | |
| ADAR1 Capital Management, LLC | 1.8% | 509,679 | +0.38% | 1.3% | $17,262,828 |
| BlackRock, Inc. | 1.8% | 486,153 | +443% | 0% | $16,466,002 |
| BOONE CAPITAL MANAGEMENT LLC | 1.7% | 470,456 | -40% | 5% | $15,934,345 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.5% | 424,862 | +836% | 0.02% | $14,390,076 |
| MPM BIOIMPACT LLC | 1.4% | 397,906 | 1.5% | $13,477,076 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.4% | 390,747 | +75% | 0.35% | $13,234,601 |